Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

about

Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

Item

http://www.wikidata.org/entity/Q49163920

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@en

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@nl

type

Item

label

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@en

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@nl

prefLabel

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@en

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@nl

P1476

Arginine methylation of EGFR: ...... stance to anti-EGFR treatment.

@en

P2093

Callisia N Clarke

http://www.w3.org/2001/XMLSchema#string

Chao-Kai Chou

http://www.w3.org/2001/XMLSchema#string

David G Menter

http://www.w3.org/2001/XMLSchema#string

Dipen M Maru

http://www.w3.org/2001/XMLSchema#string

Hsin-Wei Liao

http://www.w3.org/2001/XMLSchema#string

Ji-Yuan Wu

http://www.w3.org/2001/XMLSchema#string

Kanwal Ps Raghav

http://www.w3.org/2001/XMLSchema#string

Krittiya Korphaisarn

http://www.w3.org/2001/XMLSchema#string

Mien-Chie Hung

http://www.w3.org/2001/XMLSchema#string

Riham Katkhuda

http://www.w3.org/2001/XMLSchema#string

P2860

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

P304

2587-2599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer S Davis

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29312811

http://www.w3.org/2001/XMLSchema#string

P932

5752698

http://www.w3.org/2001/XMLSchema#string